Haemolance Plus safety lancet
DeviceHaemolance Plus safety lancet type 420 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients
NCT Number: NCT03811444
A simulated clinical use testing on the HTL-Strefa's safety lancets
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
UL LLC, Chicago, Illinois, United States
This study aims to evaluate the safety of the use of the safety lancets: Haemolance Plus, Prolance and MediSafe Solo in the prevention of NSI and to evaluate the user's opinion with regards to the handling characteristics of the medical devices.
The simulated use clinical study will involve healthcare professionals (HCPs) who routinely use safety lancets to collect blood samples.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The inclusion criteria for HCP and lay person evaluators have been chosen based on FDA guidance:
Exclusion criteria
Individuals will be excluded if:
Haemolance Plus safety lancet type 420 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients
Prolance safety lancet type 430 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
MediSafe Solo safety lancet type 520 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
Time frame: At time of testing, up to 90 minutes
Time frame: At time of testing, up to 90 minutes
Evaluator questionnaire using five-point response Likert scale (coded from 1 "strongly disagree" to 5 "strongly agree") to measure respondents' attitudes to a particular question or statement. Numbers assigned to Likert scale express a "greater than" relationship.
Time frame: At time of testing, up to 90 minutes
Evaluator questionnaire using five-point response Likert scale (coded from 1 "strongly disagree" to 5 "strongly agree") to measure respondents' attitudes to a particular question or statement. Numbers assigned to Likert scale express a "greater than" relationship.
Time frame: At time of testing, up to 90 minutes
Evaluator questionnaire using five-point response Likert scale (coded from 1 "strongly disagree" to 5 "strongly agree") to measure any and all observed needlestick injuries and device malfunctions. Numbers assigned to Likert scale express a "greater than" relationship.
Time frame: At time of testing, up to 90 minutes
Evaluator questionnaire using five-point response Likert scale (coded from 1 "strongly disagree" to 5 "strongly agree") to measure respondents' attitudes to a particular question or statement. Numbers assigned to Likert scale express a "greater than" relationship.
Time frame: At time of testing, up to 90 minutes
Evaluator questionnaire using five-point response Likert scale (coded from 1 "strongly disagree" to 5 "strongly agree") to measure respondents' attitudes to a particular question or statement. Numbers assigned to Likert scale express a "greater than" relationship.
HTL-Strefa S.A.
Industry
Simulated Clinical Use Testing to Evaluate Sharps Injury Prevention Features of HTL-STREFA's Safety Lancets (Test A)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03941717
Agnosia, Needle Stick
Guelph, Ontario, Canada
View Trial DetailsNCT04625010
Agnosia, Maternal; Procedure
Istanbul, Büyükçekmece, Turkey (Türkiye)
View Trial DetailsNCT04363788
COVID-19, Cardiac Arrest
Warsaw, Poland
View Trial DetailsNCT03612843
Arthralgia, Arthritis
Acworth, Georgia, United States
View Trial Details